Personalized diabetes care: study tests if some patients can safely ditch mealtime insulin

NCT ID NCT06148376

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a personalized medicine approach in 239 people with type 2 diabetes who use multiple daily insulin injections. Researchers used blood tests (C-peptide and GAD antibodies) to see if some patients could safely stop their mealtime insulin and switch to other diabetes treatments. Participants wore a continuous glucose monitor and were followed for 6 months to check blood sugar control, safety, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
discontinuation of prandial insulin and switch to other diabetes treatments if indicated
What this could lead to
If successful, this could help doctors personalize diabetes care by safely reducing insulin injections for some patients, simplifying their treatment.
What could go wrong
This is an observational study, not a controlled trial, so results may not be definitive. The approach may only work for a subset of patients and requires careful monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE DOSE INSULIN THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centres Atenció Primària Lleida, Alt Pirineu i Aran

    Lleida, Spain

  • Hospital Universitari Arnau de Vilanova

    Lleida, 25198, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.